Oragenics, Inc. Update: Janet Huffman Appointed Interim CEO

Oragenics, Inc. recently released an update for its shareholders, highlighting key developments following the closure of its public offering in September 2024. Among the notable updates, the company announced the appointment of Ms. Janet Huffman, the Chief Financial Officer, to the additional role of Interim Chief Executive Officer.

In the press release issued on January 21, 2025, Oragenics stated that since the capital raise in September 2024, significant progress has been made in various areas. This includes advancements in the formulation and device enhancements for ONP-002, the initiation of Phase II preparations, supply chain readiness, prototyping for enhanced device accessibility, and regulatory milestones achievement.

Regarding the leadership transition, Ms. Huffman was introduced as the newly appointed interim Chief Executive Officer. Her extensive background includes experience in capital raising, mergers, acquisitions, and financial planning. Notably, prior to joining Oragenics, she held the position of Chief Financial Officer for TRxADE HEALTH, Inc. and played crucial roles in various healthcare companies.

The Oragenics Board of Directors expressed confidence in Ms. Huffman’s ability to lead the company during this crucial transition period. Charles Pope, Chairman of the Board, emphasized Janet’s strategic leadership skills and deep understanding of Oragenics’ operations, making her a perfect fit to guide the company in its next phase.

From a financial perspective, Oragenics highlighted strategic resource allocations post the 2024 capital raise including investments in improved drug and device formulations, device prototyping, and patent protection efforts. The company’s immediate goals include submitting the IB package for clinical trials in Australia, establishing strategic partnerships in Australia, and dosing the first patient for Phase II clinical trials.

Ms. Huffman expressed enthusiasm for the upcoming year, positioning Oragenics for significant advancements. She underscored the company’s commitment to innovation, strategic focus, and mission to create lasting value for stakeholders and patients alike.

Investors seeking more information can contact Rich Cockrell at 404.736.3838 or via email at [email protected]. For further details on Oragenics and its initiatives, please visit www.oragenics.com.

The communication contains forward-looking statements based on management’s beliefs and available information, subject to multiple risks and uncertainties. Investors are advised to proceed cautiously and evaluate all information provided.

Please note that all information is current as of the release date and is subject to change based on future developments or legal requirements.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Oragenics’s 8K filing here.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.